







an Open Access Journal by MDPI

Ocular Inflammation and Neuroimmunology

Guest Editor:

Dr. Matthew Rutar

University of Melbourne, Parkville 3010. Australia

Deadline for manuscript submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

This Special Issue focuses on inflammation in ocular diseases and neuroimmunology research. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the special issue on Ocular Inflammation and Neuroimmunology. We look forward to receiving and welcome your contributions.

Keywords:

- Neuroimmune
- Retinal inflammation
- Retinal degeneration
- Innate immune signaling cascades
- Stem Cell
- Macrophage
- Chemokine
- Receptor

Dr. Matthew Rutar *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us